[Clinical benefit of eribulin (Halaven®) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms]

Nihon Yakurigaku Zasshi. 2016;148(6):329-333. doi: 10.1254/fpj.148.329.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Differentiation / drug effects
  • Clinical Trials as Topic
  • Furans / therapeutic use*
  • Humans
  • Ketones / therapeutic use*
  • Sarcoma / drug therapy*

Substances

  • Antineoplastic Agents
  • Furans
  • Ketones
  • eribulin